New treatments for Prader-Willi Syndrome and hemophilia; FDA fast tracks a chlamydia vaccine candidate; over-the-counter test cleared for identifying chlamydia, gonorrhea and trichomoniasis.

Having more choices about the treatment of hemophilia is empowering, but it also comes with challenges, columnist Jennifer Lynne writes.

This week, the FDA approved Sanofi’s SNY hemophilia therapy, fitusiran, Novartis’ NVS Vanrafia for the reduction of ...

Sangamo, which has been having cash problems, will receive $18 million upfront in licensing fees for its AAV capsid that has ...

Sangamo Therapeutics has stacked up $18 million cash from Eli Lilly in a licensing deal that will let the pharma use the ...

Centessa Pharmaceuticals plc shifts focus to ORX750 for sleep disorders after discontinuing SerpinPC. Click here to find out ...

The U.S. Food and Drug Administration has approved Sanofi's Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce ...

The Great Lakes Hemophilia Foundation will host its 13th annual Milwaukee’s Best Bloody event, offering samples of Bloody Mary cocktails prepared by local bars and restaurants.The ...

The approval came on the basis of two randomized clinical trials that had 177 adult and pediatric male patients with either ...

EconoTimes is a global, independent publication that delivers comprehensive news, analysis, and insights on the economy, finance, and markets. Based in Korea, we offer a unique perspective on global ...

We recently published a list of 7 Most Profitable Biotech Stocks To Buy Right Now. In this article, we are going to take a ...

Sanofi's Qfitlia gains FDA approval, offering fewer injections in hemophilia care. Check out my recommendation for SNY stock.